Skip to content
10-Q

Quarterly Report

PMV PHARMACEUTICALS, INC. PMVP

0001193125-26-218227

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 12, 2026 53.33M sh
Shares Diluted Q1 2026 · Mar 31, 2026 53.33M sh
Shares Diluted Q1 2026 · Mar 31, 2025 51.95M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $4K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$19.68M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$18.27M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $39.13M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $37.98M
Stockholders Equity Q1 2026 · Mar 31, 2026 $87.97M
Stockholders Equity Q1 2026 · Dec 31, 2025 $104.71M
Stockholders Equity Q1 2026 · Mar 31, 2025 $160.11M
Stockholders Equity Q1 2026 · Dec 31, 2024 $176.08M
Current Liabilities Q1 2026 · Mar 31, 2026 $8.6M
Current Liabilities Q1 2026 · Dec 31, 2025 $11.42M
Total Liabilities Q1 2026 · Mar 31, 2026 $8.6M
Total Liabilities Q1 2026 · Dec 31, 2025 $11.85M
Current Assets Q1 2026 · Mar 31, 2026 $95.78M
Current Assets Q1 2026 · Dec 31, 2025 $115.23M
Total Assets Q1 2026 · Mar 31, 2026 $96.56M
Total Assets Q1 2026 · Dec 31, 2025 $116.56M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.34
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.34
Eps Basic Q1 2026 · Mar 31, 2026 −$0.34
Eps Basic Q1 2026 · Mar 31, 2025 −$0.34
Sga Expense Q1 2026 · Mar 31, 2026 $3.69M
Sga Expense Q1 2026 · Mar 31, 2025 $4.12M
Rd Expense Q1 2026 · Mar 31, 2026 $15.33M
Rd Expense Q1 2026 · Mar 31, 2025 $17.44M
Net Income Q1 2026 · Mar 31, 2026 −$18.04M
Net Income Q1 2026 · Mar 31, 2025 −$17.44M
Operating Income Q1 2026 · Mar 31, 2026 −$19.02M
Operating Income Q1 2026 · Mar 31, 2025 −$21.56M